



Speakers



Emerich Grassinger
Takeda



Armin Groh
CSL Behring



Dr Reto Theis
Merck



Dr Thomas Storm
Novartis Pharma

Quality Control of Starting Materials (APIs and Excipients)

6/7 February 2020 | Munich, Germany



*Testing and Sampling of
Incoming Active Pharmaceutical Ingredients (APIs) and Excipients*

Highlights

- Regulatory Requirements for APIs and Excipients
- Current GMP Requirements for APIs, Excipients and Drug Products
- Laboratory Organisation
- Pharmacopoeias
- Sampling of Incoming APIs and Excipients
- Reduced Testing of Supplied APIs and Excipients
- Analytical Methods
- NIR (Near InfraRed Spectroscopy) and Raman for an Efficient Control of Starting Materials

Actual Challenges :

- Risk Assessment for Representative Sampling
- New Requirements for Excipients

Objective

Testing active pharmaceutical ingredients and excipients is one of the main tasks of the quality control units in the pharmaceutical industry. It must be ensured that the necessary tests are conducted on the incoming goods and that the starting materials are released only after their quality was judged as satisfactory. This GMP Education Course about the incoming goods control of APIs and excipients will give you a comprehensive overview of the specific tasks and questions of the “starting materials lab” and show you real-life solutions and answers.

This course will deal among others with the following questions:

- Who is responsible for the release or rejection of starting materials?
- How can the incoming goods lab be organised efficiently?
- Which SOPs are necessary?
- In which cases can test results be taken over from the supplier’s certificate of analysis?
- Do all test items of a pharmacopoeial monograph have to be analysed?
- Are the pharmacopoeial monographs similar, or must different tests be conducted for Ph.Eur., USP and JP?
- Can a pharmacopoeial test method be replaced by an alternative test method? Does this require a variation application?
- How can the EU Guideline 2015/C 95/02 on risk assessment for excipients be implemented?

It is the aim of this GMP Education Course to give answers to these and many other important questions relating to the testing of APIs and excipients and to serve as a forum for an intensive experience exchange.

Target Audience

This GMP Education Course is directed at all those employees from quality control units in the pharmaceutical industry (including heads of quality control and laboratory managers) who are competent or responsible for sampling, testing and release of the starting materials used (= APIs and excipients). This course is also of interest to personnel from quality assurance and to those employees from API and excipient manufacturers who want to inform themselves about the requirements of the pharmaceutical industry on the testing of these starting materials.

Social Event



At the end of the first course day you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.

Programme

Regulatory Requirements for APIs and Excipients

- Definition of APIs and excipients
- EU Requirements
- FDA Requirements, e.g. FDA Draft Guidance “Drug Product”
- Common Technical Document (CTD)
- Certification Procedures:
 - EDQM Certificate of Suitability
 - Active Substance Master File
 - US - Drug Master File
- Quality Standards: How to discern a good starting material from a bad one?
- New requirements for excipients

Current GMP Requirements for APIs, Excipients and Drug Products

- Relevant ICH guidelines
- EU regulations for Drug Products and API
- GMP for excipients – current expectations
- IPEC (International Pharmaceutical Excipients Council) Guideline for excipients
- Upcoming EU GMP regulation for excipients
- GMP aspects of supplier/manufacture qualification
- New challenge: risk assessment for excipients

Laboratory Organisation

- Role of the raw materials laboratory within the pharmaceutical supply chain
- Optimization of the analytical laboratory with respect to costs, time and resources (economic order size, costs of analysis vs stock keeping costs, reduced sampling and reduced testing, ABC analysis)

Pharmacopoeias

- Regulatory background
- Pharmacopoeial institutions – Ph.Eur., USP/NF, JP
- CEPs
- Implementation of pharmacopoeial monographs in your laboratory
- Multi-compendial testing
- Validation of pharmacopoeial testing methods
- USP General Chapter <1226> Verification of Compendial Methods

Sampling of Incoming APIs and Excipients

- Regulatory requirements
- Reduced Testing
- Sampling plans
- Rational for representative sample and risk analysis
- Training
- GMP-compliant documentation of sampling operations
- Practical examples



WORKSHOP I Sampling

- Examples for generating sample procedures
- Risk assessment and Rational for representative sampling
- Calculating different optimizations (reduced sampling, reduced testing, economic order size)

Reduced Testing of Supplied APIs and Excipients

- What guidance is available on reduced QC testing?
- EU- and FDA expectations?
- Supplier qualification as a prerequisite
- Other information required before you start reducing
- Can APIs and excipients be covered within the same approach?
- Who is in the driver seat, who must be involved?
- Practical execution



WORKSHOP II Reduced Testing

Apart from any guidance, it is still much up to the manufacturer to decide which APIs and which excipients might be subject of a reduced testing procedure. Since the quality of the substance has to be assured without compromise, multiple factors must be considered before the full testing of every single batch can be reduced. It is the aim of this workshop to exchange information about different approaches and to discuss their advantages and disadvantages respectively considering the actual guidance as well as their practicability.

Analytical Methods

- Use and validation of non-compendial methods
- How to proof comparability?
- Advantages of instrumental methods versus visual methods
- Handling of deviations (Out-of-Specification results and complaints)
- Measurement system analysis
- Documentation
- Retests

NIR (Near InfraRed Spectroscopy) for an Efficient Control of Starting Materials

- A short introduction to NIR-Spectroscopy
- NIR as a pharmacopoeial monograph
- NIR for single container identification
- Costs vs. benefit
- NIR vs. ATR vs. Raman

Speakers



Emerich Grassinger
Takeda, Vienna, Austria

Emerich Grassinger works since 1995 in various positions for the pharmaceutical industry within QA and QC. From 2002-2010 he headed several labs within Boehringer Ingelheim and was there also responsible for the Raw Material laboratory in which the testing and release of the APIs and Excipients was carried out. He led several improvement projects throughout the supply chain involving the raw material releasing process. 2010 he joined Haupt Pharma Wuelfing, where he was responsible for Quality Control, including the raw material laboratory and the sampling of incoming goods. Since 2019 he is head of Quality Control at Takeda in Vienna, Austria.



Armin Groh
CSL Behring, Bern, Switzerland

Armin Groh worked many years as manager of several laboratory groups in the QC unit of Takeda in Singen, Germany. He was responsible for the release of starting materials and for various analytical methods like HPLC, GC, FT-IR and FT-NIR, titrations, and other pharmacopoeial methods. In April 2018 he joined CSL Behring as Global Lead Auditor.



Dr. Reto Theiss
Merck Healthcare, Darmstadt, Germany

Dr Reto Theiss started his career in the pharmaceutical industry in 1999. Since 2002 he is with Merck Healthcare in Darmstadt, Germany, acting as a Qualified Person where he was initially responsible for releasing products of the generic branch to the market. Since 2005 his duties include the QA supervision of solid dosage forms during the whole production chain. Furthermore, he is performing supplier and CMO audits as part of the supplier qualification.



Dr Thomas Storm
Novartis Pharma AG, Basel, Switzerland

Thomas Storm studied Chemistry and Physics, PhD in Environmental Technology, TU Berlin. Worked since 2001 as Head of Laboratory in Analytical Development at Schering AG / Bayer Schering Pharma AG, Berlin. Joined Novartis Pharma AG in Basel in Inhalation Technical Development in 2008, currently leading the oral pharmaceutical development unit. Work areas included quality control of excipients, supplier qualification, quality control for development candidates, electronic raw data archival, HPLC, HPLC/MS, CDS, and inhalation pharmaceutical development of oral and inhaled dosage forms.

If the bill-to-address deviates from the specifications on the right, please fill out here:

Reservation Form (Please complete in full)

Quality Control of Starting Materials (APIs and Excipients), 6/7 February 2020, Munich, Germany

Title, first name, surname

Department

Company

CONCEPT HEIDELBERG

P.O. Box 101764

Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg

GERMANY

Important: Please indicate your company's VAT ID Number

Purchase Order Number, if applicable

City

Country

Phone / Fax

E-Mail (Please fill in)

General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge the following processing fees:

- Cancellation until 2 weeks prior to the conference 10%.

- Cancellation until 1 week prior to the conference 50%.

- Cancellation within 1 week prior to the conference 100%.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors,

or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible

and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be re-

sponsible for discount airfare penalties or other costs incurred due to a cancel-

lation.

Terms of payment: Payable without deductions within 10 days after receipt of

invoice.

Important: This is a binding registration and above fees are due in case of can-

cellation or non-appearance. If you cannot take part, you have to inform us in

writing. The cancellation fee will then be calculated according to the point of

time at which we receive your message.

In case you do not appear at the event without having informed us, you will have

to pay the full registration fee, even if you have not made the payment yet. Only

after we have received your payment, you are entitled to participate in the con-

ference (receipt of payment will not be confirmed!) (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal

Data. Concept Heidelberg will use my data for the processing of this order,

for which I hereby declare to agree that my personal data is stored and pro-

cessed. Concept Heidelberg will only send me information in relation with this

order or similar ones. My personal data will not be disclosed to third parties (see

also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I

note that I can ask for the modification, correction or deletion of my data at any

time via the contact form on this website.

Date

Thursday, 6 February 2020, 9.00 h – 18.00 h

(Registration and coffee 8.30 h – 9.00 h)

Friday, 7 February 2020, 8.30 h – 16.00 h

Venue

H4 Hotel München Messe

Konrad-Zuse-Platz 14

81829 Munich, Germany

Phone +49 (0)89 940083-0

Fax +49 (0)89 940083-1000

Email muenchen.messe@h-hotels.com

Fees (per delegate, plus VAT)

ECA Members € 1,590

APIC Members € 1,690

Non-ECA Members € 1,790

EU GMP Inspectorates € 895

The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.

Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form/POG when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG

P.O.Box 10 17 64

69007 Heidelberg, Germany

Phone +49(0)62 21/84 44-0

Fax +49(0)62 21/84 44 34

info@concept-heidelberg.de

www.concept-heidelberg.de

For questions regarding content please contact:

Dr Gerhard Becker (Operations Director) at

+49(0)62 21/84 44 65, or at

becker@concept-heidelberg.de.

For questions regarding reservation, hotel, organisation etc. please contact:

Mr Niklaus Thiel (Organisation Manager) at

+49(0)62 21/84 44 43, or at

thiel@concept-heidelberg.de.